Mesa Laboratories, Inc. — Form 10-Q Summary
Reporting period: Quarter ended June 30, 2011, the first quarter of fiscal 2012. The request metadata references “2010 Q1,” but the filing itself clearly reports June 30, 2011 and compares it with June 30, 2010. Financial statements are unaudited. Mesa manufactures and distributes electronic measurement systems, disposables, biological indicators, and related repair and calibration services.
Key Financial Metrics
| Metric | Q1 FY2012 | Q1 FY2011 | Change |
|---|---|---|---|
| Sales | $8.888 million | $7.455 million | +19% |
| Gross profit | $5.388 million | $4.381 million | +23% |
| Gross margin | 60.6% | 58.8% | +1.8 percentage points |
| Operating income | $2.693 million | $2.214 million | +22% |
| Operating margin | 30.3% | 29.7% | Improved modestly |
| Net income | $1.679 million | $1.320 million | +27% |
| Diluted EPS | $0.49 | $0.40 | +23% |
| Cash flow from operations | $2.888 million | $2.586 million | +12% |
Revenue mix: Biological Indicator sales were $4.549 million, up 32%, while Instrumentation Products sales were $4.339 million, up 8%. Parts and service revenue increased to $1.103 million from $1.009 million, but declined to 12% of sales from 14%.
Balance sheet and liquidity: Cash and equivalents were $6.054 million at June 30, 2011, compared with $3.546 million at March 31, 2011. Current assets were $18.834 million and current liabilities were $9.580 million, producing working capital of $9.254 million and a current ratio of approximately 2:1. Accounts receivable were $6.543 million and inventories were $5.377 million.
Debt: Debt consisted principally of a $2.250 million reducing credit facility and a fully utilized $4.000 million revolving line. Total future debt maturities were reported at $6.250 million, including $4.750 million in fiscal 2012. The revolving line matured September 24, 2011. Interest rates were variable with a 3.25% floor. The company stated that it expected to repay the revolving line during fiscal 2012 and was in compliance with debt covenants at June 30, 2011.
Investing and financing: Capital expenditures were $161,000, compared with $2.346 million in the prior-year quarter, which included building and acquisition-related spending. Financing activities used $193,000, including $394,000 of dividends, $27,000 of treasury-stock purchases, and $250,000 of net debt repayment. The company paid a quarterly dividend of $0.12 per share.
Material Changes Versus the Prior Comparable Period
- Sales growth reflected a full quarter of SGM Biotech activity and the addition of the Apex Laboratories biological-indicator product line acquired in December 2010, together with organic growth.
- Biological Indicator revenue increased 32%, primarily from Apex products, a full quarter of Bozeman operations, and 11% organic growth in existing Omaha-based products.
- Instrumentation revenue increased 8% from organic growth.
- Gross margin improved due to higher-margin product mix, manufacturing efficiencies, materials savings, and the transfer of Torqo production in-house.
- Research and development expense increased to $408,000 from $223,000, reflecting increased product-development activity and acquired product lines.
- Amortization expense increased to approximately $376,000 from $250,000 because of acquired intangible assets. Selling, general and administrative expense increased to $2.287 million from $1.944 million.
- Cash flow from operations remained positive, while the prior-year quarter included $12.027 million of acquisition spending and $2.150 million of building-related capital expenditures.
Outlook, Risks, Contingencies and Unusual Items
- Management expected general and administrative costs to stabilize after fiscal 2011 acquisition-related increases, but anticipated a full year of higher amortization and additional personnel costs.
- Management expected Biological Indicator sales to represent a greater proportion of revenue. It also stated that Apex products could improve segment margins over time, although integration involved one-time and ongoing organizational costs.
- The company had approximately $350,000 of remaining Apex holdback obligations expected to be paid in December 2011. A $50,000 amount was being withheld pending resolution of purchased accounts receivable matters.
- The company maintained a plan to repurchase up to 300,000 shares but was minimizing buybacks because of lower cash and higher debt. It repurchased 11,362 shares for approximately $27,000 during the quarter.
- Principal risks included economic conditions, competition across its data logging, dialysis, fluid measurement, biological-indicator and bottlecap torque-testing markets, personnel performance, business-strategy changes, and unusual items from strategic evaluations.
- The filing reported no legal proceedings and no material change in previously disclosed risk factors. Management concluded that disclosure controls were effective and that there were no material changes in internal control over financial reporting.
- Market exposure primarily involved variable-rate, dollar-denominated investments and variable-rate debt.
Investor Verification Checklist
- Verify the refinancing or repayment status of the $4.000 million revolving credit line that matured September 24, 2011.
- Assess the company’s ability to meet fiscal 2012 debt maturities of $4.750 million while continuing dividends and potential acquisitions.
- Review organic growth, integration progress, and margin performance for the Apex and SGM Biotech businesses.
- Monitor amortization, research and development, personnel, and other acquisition-related costs relative to revenue growth.
- Evaluate receivables quality, including the $50,000 Apex holdback and the company’s elevated 67-day days-sales-outstanding measure.
- Confirm that subsequent results support management’s expectation of continued cash generation and repayment of revolving debt.